---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-24-000018"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:08:01.879684+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio Q3 net loss $2.6M; cash raised to $17.9M via PIPE; enters AstralBio collaboration

## Summary
- Net loss from continuing ops: $2.6M ($0.71/share) vs $6.3M ($9.53/share) YoY; no revenue.
- R&D expenses down 66%, G&A down 23% YoY under cash preservation strategy.
- Cash and equivalents $17.9M after $15M PIPE closed in April, up from $6.4M at March 31.
- Partnered with AstralBio to develop 4 antibody targets for obesity/cardiometabolic diseases.
- Sold early-stage PD-1 asset to Otsuka for $1M upfront and up to $52.5M in contingent payments.

## SEC filing metadata
- accession: 0001420720-24-000018
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/0001420720-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/ibio-20240513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-24-000018
- JSON: https://secwatch.observer/filing/0001420720-24-000018.json
- Plain text: https://secwatch.observer/filing/0001420720-24-000018.txt

## Key facts
- Earnings Releases
  iBio, Inc. reported financial results for third quarter ended March 31, 2024.
  - Period: third quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/0001420720-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.